---
title: "Ocrevus (ocrelizumab) in multiple sclerosis: Drug interactions questions"
description: "Drug interactions questions on Ocrevus (ocrelizumab) in multiple sclerosis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Can Ocrevus be used with other immunosuppressants or MS therapies? What drug interactions does Ocrevus have? 2 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/drug-interactions"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Ocrevus (ocrelizumab) in multiple sclerosis: Drug interactions questions

Manufacturer: Genentech, Inc.  
Prescribing information: [Ocrevus](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf), [Ocrevus Zunovo](https://www.gene.com/download/pdf/ocrevus_zunovo_prescribing.pdf)

Questions that apply to every indication of Ocrevus are on [Ocrevus (ocrelizumab), all indications](https://www.evicenter.com/medical-information/ocrevus).

## Drug interactions

<a id="ocrevus-other-immunosuppressants"></a>

### Can Ocrevus be used with other immunosuppressants or MS therapies?

> “When initiating treatment with ocrelizumab after an immunosuppressive therapy or initiating an immunosuppressive therapy after ocrelizumab-containing products, consider the potential for increased immunosuppressive effect. Treatment with ocrelizumab has not been studied in combination with other MS therapies.”

Source: [OCREVUS: Important Safety Information for HCPs, captured 2026-11-12](https://www.ocrevus-hcp.com/safety.html#:~:text=When%20initiating%20treatment%20with%20ocrelizumab,combination%20with%20other%20MS%20therapies.)

<a id="ocrevus-drug-interactions"></a>

### What drug interactions does Ocrevus have?

> “7 
> DRUG INTERACTIONS  
> 7.1 
> Immunosuppressive or Immune-Modulating Therapies  
> The concomitant use of OCREVUS and other immune-modulating or immunosuppressive therapies, including 
> immunosuppressant doses of corticosteroids, is expected to increase the risk of immunosuppression. Consider 
> the risk of additive immune system effects when coadministering immunosuppressive therapies with 
> OCREVUS. When switching from drugs with prolonged immune effects, such as daclizumab, fingolimod, 
> natalizumab, teriflunomide, or mitoxantrone, consider the duration and mode of action of these drugs because of 
> additive immunosuppressive effects when initiating OCREVUS [see Warnings and Precautions (5.2)].  
> 7.2  Vaccinations 
> A Phase 3b randomized, open-label study examined the concomitant use of OCREVUS and several non-live 
> vaccines in adults 18-55 years of age with relapsing forms of MS (68 subjects undergoing treatment with 
> OCREVUS at the time of vaccination and 34 subjects not undergoing treatment with OCREVUS at the time of 
> vaccination). Concomitant exposure to OCREVUS attenuated antibody responses to tetanus toxoid-containing 
> vaccine, pneumococcal polysaccharide, pneumococcal conjugate vaccines, and seasonal inactivated influenza 
> vaccines. The impact of the observed attenuation on vaccine effectiveness in this patient population is unknown. 
> The safety and effectiveness of live or live-attenuated vaccines administered concomitantly with OCREVUS 
> have not been assessed [see Warnings and Precautions (5.2)].”

Source: [OCREVUS: OCREVUS \[IV\], page 15, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=15)

Note: The passage is section 7 (Drug Interactions) of the OCREVUS (intravenous) Prescribing Information.

## Related pages
- [Medical information: Ocrevus (ocrelizumab): Multiple sclerosis](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis)
- [Indication](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/storage-and-supply)
